Randomized, Double-Blind, Parallel Group Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BMS-936558 (Nivolumab) in Participants With Severe Sepsis or Septic Shock.
Phase of Trial: Phase I
Latest Information Update: 29 Jan 2018
At a glance
- Drugs Nivolumab (Primary)
- Indications Sepsis
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Bristol-Myers Squibb
- 22 Jan 2018 Status changed from active, no longer recruiting to completed.
- 06 Nov 2017 Planned End Date changed from 12 Jan 2018 to 28 Dec 2017.
- 06 Nov 2017 Planned primary completion date changed from 11 Jan 2018 to 28 Dec 2017.